| 1 |
34078115 | Impact of Interferons and Biological Drug Inhibitors of IL-2 and IL-6 on Small-Molecule Drug Metabolism Through the Cytochrome P450 System. | 2022 Feb |
1 |
| 2 |
34459464 | Severe adverse cutaneous reactions induced by gefitinib combined with antihypertensive and antihyperlipidemic drugs in lung cancer: a case report. | 2022 Jan 1 |
1 |
| 3 |
33277702 | Statin-induced rhabdomyolysis from azithromycin interaction in a patient with heterozygous SLCO1B1 polymorphism. | 2021 Jun |
1 |
| 4 |
33459228 | HMG-CoA Reductase Inhibitors (Statins) and their Drug Interactions Involving CYP Enzymes, P-glycoprotein and OATP Transporters-An Overview. | 2021 |
1 |
| 5 |
34606062 | Role of Drug-Gene Interactions and Pharmacogenetics in Simvastatin-Associated Pulmonary Toxicity. | 2021 Nov |
1 |
| 6 |
32351149 | Predictive pharmacogenetic biomarkers for breast cancer recurrence prevention by simvastatin. | 2020 Sep |
1 |
| 7 |
32729746 | An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins. | 2020 Sep |
1 |
| 8 |
30808332 | Severe rhabdomyolysis-induced acute kidney injury following concomitant use of Genvoya® (EVG/COBI/FTC/TAF) and simvastatin; a case report. | 2019 Feb 26 |
1 |
| 9 |
30887238 | Simulating the Impact of Elevated Levels of Interleukin-6 on the Pharmacokinetics of Various CYP450 Substrates in Patients with Neuromyelitis Optica or Neuromyelitis Optica Spectrum Disorders in Different Ethnic Populations. | 2019 Mar 18 |
1 |
| 10 |
31640597 | Palbociclib in combination with simvastatin induce severe rhabdomyolysis: a case report. | 2019 Oct 22 |
1 |
| 11 |
29063606 | Harnessing Meta-analysis to Refine an Oncology Patient Population for Physiology-Based Pharmacokinetic Modeling of Drugs. | 2018 Feb |
1 |
| 12 |
29255993 | Prevalence and nature of statin drug-drug interactions in a university hospital by electronic health record mining. | 2018 Apr |
2 |
| 13 |
27722854 | Disease-Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis. | 2017 Jun |
1 |
| 14 |
28350522 | The influences of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin, in relation to CYP3A4 inhibition. | 2017 Apr |
3 |
| 15 |
29167415 | Ticagrelor Leads to Statin-Induced Rhabdomyolysis: A Case Report. | 2017 Nov 23 |
1 |
| 16 |
26502771 | Voriconazole-Induced Hepatitis via Simvastatin- and Lansoprazole-Mediated Drug Interactions: A Case Report and Review of the Literature. | 2016 Jan |
1 |
| 17 |
26765458 | Risks of Adverse Events Following Coprescription of Statins and Calcium Channel Blockers: A Nationwide Population-Based Study. | 2016 Jan |
2 |
| 18 |
27605198 | Statin-associated rhabdomyolysis triggered by drug-drug interaction with itraconazole. | 2016 Sep 7 |
1 |
| 19 |
25274942 | No effect of CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) on lipid-lowering response to statins in Greek patients with primary hypercholesterolemia. | 2015 Mar |
2 |
| 20 |
25324279 | Physiologically based pharmacokinetic modeling to predict drug-drug interactions involving inhibitory metabolite: a case study of amiodarone. | 2015 Feb |
1 |
| 21 |
25747989 | Carboxylesterase 1-mediated drug-drug interactions between clopidogrel and simvastatin. | 2015 |
3 |
| 22 |
25932626 | Co-medication of statins with contraindicated drugs. | 2015 |
3 |
| 23 |
26164721 | Individual and Combined Associations of Genetic Variants in CYP3A4, CYP3A5, and SLCO1B1 With Simvastatin and Simvastatin Acid Plasma Concentrations. | 2015 Jul |
1 |
| 24 |
26736984 | Pharmacokinetic model for the inhibition of simvastatin metabolism by itraconazole. | 2015 |
1 |
| 25 |
23965645 | Development of a pharmacokinetic interaction model for co-administration of simvastatin and amlodipine. | 2014 |
2 |
| 26 |
24379677 | Pharmacokinetic drug-drug interactions between 1,4-dihydropyridine calcium channel blockers and statins: factors determining interaction strength and relevant clinical risk management. | 2014 |
2 |
| 27 |
24430948 | Lack of association of the p450 oxidoreductase *28 single nucleotide polymorphism with the lipid-lowering effect of statins in hypercholesterolemic patients. | 2014 Jun |
1 |
| 28 |
24865757 | Lomitapide: A novel agent for the treatment of homozygous familial hypercholesterolemia. | 2014 Jun 15 |
1 |
| 29 |
24927617 | Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin. | 2014 Jul-Aug |
1 |
| 30 |
24974574 | Effect of thyroid hormone status and concomitant medication on statin induced adverse effects in hyperlipidemic patients. | 2014 Jun |
1 |
| 31 |
25041770 | Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin. | 2014 Jul |
2 |
| 32 |
25051018 | CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort. | 2014 Oct |
7 |
| 33 |
25571290 | A pharmacokinetic drug-drug interaction model of simvastatin and clarithromycin in humans. | 2014 |
1 |
| 34 |
25571292 | A pharmacokinetic drug-drug interaction model of simvastatin and verapamil in humans. | 2014 |
1 |
| 35 |
25571293 | Pharmacokinetic modeling of simvastatin, nelfinavir and their interaction in humans. | 2014 |
2 |
| 36 |
23252946 | Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia. | 2013 Jan |
1 |
| 37 |
23314529 | CYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid control. | 2013 |
2 |
| 38 |
23334403 | Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatin. | 2013 Jun |
2 |
| 39 |
23492463 | Ranolazine-induced myopathy in a patient on chronic statin therapy. | 2013 Mar |
1 |
| 40 |
23703578 | Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. | 2013 Oct |
3 |
| 41 |
23732466 | CYP3A4-catalyzed simvastatin metabolism as a non-invasive marker of small intestinal health in celiac disease. | 2013 Aug |
1 |
| 42 |
23930676 | Genetic variation in the PPARA gene is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. | 2013 Aug |
1 |
| 43 |
23939663 | Reduced exposure variability of the CYP3A substrate simvastatin by dose individualization to CYP3A activity. | 2013 Nov |
5 |
| 44 |
24256019 | [Hypolipidemic agents drug interactions: approach to establish and assess its clinical significance. Structured review]. | 2013 Nov-Dec |
1 |
| 45 |
21730017 | Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist. | 2012 Aug |
1 |
| 46 |
21820929 | [Specific considerations on the prescription and therapeutic interchange of statins]. | 2012 Mar-Apr |
2 |
| 47 |
22014153 | Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. | 2012 Apr |
4 |
| 48 |
22176629 | Effect of posaconazole on the pharmacokinetics of simvastatin and midazolam in healthy volunteers. | 2012 Jan |
1 |
| 49 |
22237927 | Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population. | 2012 May |
3 |
| 50 |
22281720 | Impact of CYP2D6 polymorphisms on the pharmacokinetics of lovastatin in Chinese subjects. | 2012 Jun |
1 |